Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

INTRODUCTION: Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion–positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001, STARTRK-1, and STARTRK-2 trials is presented, with substantially longer follow-up, more patients, and the first description of...

Descripción completa

Detalles Bibliográficos
Autores principales: Drilon, Alexander, Chiu, Chao-Hua, Fan, Yun, Cho, Byoung Chul, Lu, Shun, Ahn, Myung-Ju, Krebs, Matthew G., Liu, Stephen V., John, Thomas, Otterson, Gregory A., Tan, Daniel S.W., Patil, Tejas, Dziadziuszko, Rafal, Massarelli, Erminia, Seto, Takashi, Doebele, Robert C., Pitcher, Bethany, Kurtsikidze, Nino, Heinzmann, Sebastian, Siena, Salvatore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160474/
https://www.ncbi.nlm.nih.gov/pubmed/35663414
http://dx.doi.org/10.1016/j.jtocrr.2022.100332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160474/
https://www.ncbi.nlm.nih.gov/pubmed/35663414
http://dx.doi.org/10.1016/j.jtocrr.2022.100332

Ejemplares similares